A Study On Disease On Obesity (Substance P)

Abstract

This review investigates the role of the neuropeptide Substance P (SP) in two increasingly prevalent conditions: obesity and inflammatory bowel disease (IBD). SP, a member of the tachykinin family, plays a significant role in neurogenic inflammation and is implicated in intestinal motility, mucosal permeability, and fat tissue metabolism. The study explores how SP contributes to the link between increased adiposity and gut inflammation, highlighting its involvement in the pathogenesis of IBD, including Crohn’s disease and ulcerative colitis. Recent studies indicate that SP influences immune cell recruitment, cytokine release, and fat depot inflammation factors that are central to both obesity and IBD progression. Additionally, SP may regulate appetite suppression, fat breakdown, and insulin sensitivity, offering potential therapeutic benefits. However, its clinical application is limited by a lack of human studies and unclear mechanisms. Adverse effects such as gastrointestinal discomfort have also been noted. Despite these challenges, emerging evidence positions SP as a potential target for managing metabolic and inflammatory disorders. Further research is needed to elucidate its mechanisms and validate its therapeutic relevance in humans.